Predicting acute ovarian failure in female survivors of childhood cancer: a cohort study in the Childhood Cancer Survivor Study (CCSS) and the St Jude Lifetime Cohort (SJLIFE).
read more
Citations
Small cell carcinoma of the ovary hypercalcemic type (SCCOHT): Comprehensive management of a newly diagnosed young adult.
Review - late toxicity of abdominal and pelvic radiotherapy for childhood cancer.
Novel therapies for childhood cancer and impact on puberty
Fertility status in childhood cancer survivors of hematological malignancies: a systematic review
Ovarian tissue cryopreservation in young females with cancer and its impact on ovarian follicle density.
References
Random Forests
Assessing the performance of prediction models: a framework for traditional and novel measures.
Clinical Ascertainment of Health Outcomes Among Adults Treated for Childhood Cancer
Psychological impact of infertility.
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
Frequently Asked Questions (10)
Q2. What have the authors stated for future works in "Predicting acute ovarian failure in female childhood cancer survivors: a cohort study in the childhood cancer survivor study (ccss) and the st. jude lifetime cohort (sjlife) authorship list line" ?
Their goal was to develop and validate an easily accessible and user-friendly clinical tool to aid clinicians at the time of cancer diagnosis by providing personalised risk assessments of future ovarian function for patients. The outstanding performance in the external SJLIFE cohort further confirms that their prediction algorithms are generalisable. CCSS participant ovarian status was not verified clinically, and thus subject to potential misclassification. 8,22,23 Although the authors developed the models using the outcome data with a higher potential for misclassification, they observed an increase in the predictive ability in the SJLIFE cohort, which highlights the robustness of their models.
Q3. What is the main focus of cancer survivorship research?
As the majority of childhood cancer patients will become long-term survivors, the focus of cancer survivorship research has shifted toward maximizing survivor quality of life.
Q4. How many CCSS survivors had a HSCT?
Almost one-third (1,869 (31·8%) of 5,886) of the CCSS survivors had been diagnosed with leukaemia, and 3·7% (217 of 5,886) underwent a HSCT.
Q5. What predictors were used in the CCSS and SJLIFE models?
Common predictors in both models were history of hematopoietic stem cell transplantation (HSCT), cumulative alkylating agent dose, and an interaction between age at cancer diagnosis and HSCT.
Q6. How many survivors were diagnosed with AOF in the CCSS sample?
Three hundred and fifty-three of 5,886 survivors were classified with AOF in the CCSS sample, corresponding to a prevalence of 6·0%.
Q7. What was the ovarian dose model AUC value?
The ovarian dose model AUC value was 0·94 (95% CI = 0·90-0·98), and the prescribed dose model AUC value was 0·96 (95% CI = 0·94-0·97).
Q8. How much is the prevalence of premature menopause in CCSS female survivors?
In the general population, the prevalence of premature, non-surgical menopause is approximately 1%,11 whereas the cumulative incidence of PM (excluding AOF) reported in CCSS female survivors is 9% by age 4010.
Q9. What was the AP value for the ovarian dose model?
For internal validation using the CCSS test sets, the AP value was 0·50 (95% CI = 0·45-0·56) for the ovarian dose model and 0·37 (95% CI = 0·32-0·43) for the prescribed dose model.
Q10. What is the affiliation between MD Anderson and the St Jude Hospital Research Center?
MD Anderson Late Effects Group (RMH and SAS) has a subcontract with St Jude Hospital Research Center for CCSS dosimetry and also a contract from REB/NCI to perform dosimetry on various studies.